Child ; Cleidocranial Dysplasia ; diagnosis ; diagnostic imaging ; Humans ; Male ; Radiography

Clinical studies have shown that trastuzumab combined with chemotherapy can significantly improve survival in treatment of HER2-positive metastatic breast cancer as well as in the neoadjuvant and adjuvant therapy for HER2-positive early breast cancer. In patients with HER2-positive and hormone receptor-positive metastatic breast cancer, adding trastuzumab to endocrine therapy improves treatment efficacy. Resistance to trastuzumab may be reversed by incorporating other targeted therapeutic drugs. Patients can still benefit from continuing trastuzumab after their disease progresses.

Aim To establish an animal model of uterine leiomyoma for pathogenesis research and drug screen analysis.Methods Guinea pigs were treated with estradiol benzoate 100 ?g?d~(-1),twice a week,by intramuscular injection for 12 weeks.After the animal were killed,the uteri were dissected out and ultrathin sections were obtained.Compare to that of human being,pathohistologic characteristics were observed under the microscope.Results The uteri treated with estrogen were proliferated and deformated.Uterine nodules were observed in many of the tested animals.According to the results of pathohistology,these cells demonstrate the features of smooth muscle-like cells.Conclusion The uterine leiomyoma induced by estrodiol in guinea pig is similar to that of human being.It has been suggested that the animal model is valuable for pathogenesis research and drug screen analysis,although it still needs more evidence to be demonstrated.

OBJECTIVE To study the classification and distribution of the ?-lactamases produced by Escherichia coli in diabetic patients.METHODS To detect the ?-lactamases produced by E.coli in diabetic patients with a multi-disk synergy test.RESULTS Forty-nine strains of 60 strains in our study produced the ?-lactamases with total positive rate of 81.67%,From them 5 strains were producing penicillinases,17 strains producing BSBLs(28.33%),and 27 strains were producing ESBLs(45.00%),no carbapenem-hydrolyzing ?-lactamases were detected.In 27 strains producing ESBLs,the sensitivities to the ceftazidime,aztreonam and cefotaxime were similar.CONCLUSIONS The types of ?-lactamases produced by E.coli in diabetic patients are mainly BSBLs and ESBLs,without carbapenem-hydrolyzing ?-lactamases;the sensitivities to the ceftazidime,aztreonam and cefotaxime are similar.

The incidence of vascular cognitive impairment is increasing year by year.Its medical burden is getting worse, therefore, there is an urgent need to delay and prevent its occurrence and development.Active symptomatic treatment and targeted intervention of vascular risk factors may alleviate the progress of disease to a certain extent.This article reviews the advances in the treatment and prevention of vascular cognitive impairment.

The development of formulas in the Ming Dynasty surpassed the previous dynasties in range and depth.The main achievements of formulas were not only the coming out of Puji Fang and Yifang Kao,but also the diversity of formulas nomenclature and variation,initial perfection of formulas classification and composition,continuous invention of new distinctive formulas,steady increment of remedy books and wide application of preparations.

In the 58th American Society of Hematology Annual Meeting, some clinical results on B-cell lymphoma were reported. This review will focus on the recent progress of diffuse large B-cell lymphoma and mantle cell lymphoma in this annual meeting.

Ligustrazine is one of the active ingredients of chuanxiong. Modern medical research indicated that ligustrazine had the effect of improving microcirculation, anti-inflammatory, anti-fibrosis, which showed the potential function of ligustrazine in the prevention and treatment of postoperative abdominal adhesions. The basic theory of traditional Chinese medicine (TCM) also believed that ligustrazine had the unique double effect of regulating both qi and blood. Therefore, ligustrazin had broad research and application prospects in the prevention and treatment of postoperative abdominal adhesions. This article reviewed studies of ligustrazine in the prevention and treatment of postoperative abdominal adhesions in recent years from four aspects, which were theoretical basis, clinical application, mechanism research and pharmaceutical dosage forms. It identified the research status and advantages of ligustrazine in the prevention and treatment of postoperative abdominal adhesions. It also pointed out shortages in the clinical application, such as unstandardized medication, small sample size study and etc. There were insufficient deep and clear studies in the research of mechanism. In the aspect of pharmaceutical dosage forms, the thinking should be expanded with innovation. It will provide basis and direction for research and application in the future, in order to further elucidate mechanisms in the prevention and treatment of postoperative abdominal adhesions as well as provide theory basis, research thinking and methods for the real display of advantages in TCM.

Cancer cells frequently share biological characteristics and energy metabolic processes distinct from normal cells. The specific metabolic phenotype was originally known as the Warburg effect. Researchers later discovered that cancer cells prefer to synthesize fatty acid de novo . Moreover, key enzymes involved in fatty acid synthesis and β-oxidation are overexpressed in tumor tissues, with low or without expression in normal tissues. Abnormal fatty acid metabolism is related to the survival and invasiveness of cancer cells, indicating that abnormal fatty acid metabolism provides the crucial components and energy sources of cancer cells. In recent years, the specific phenotype of abnormal fatty acid metabolism and the exploration of the role of this metabolic alteration in cancer biology and therapeutic strategies targeting the fatty acid metabolic pathways have become attractive focuses in cancer research. The role of active fatty acid metabolism in tumorigenesis and development, as well as the research progress in the development of the specific inhibitors, is reviewed in this paper.

Cutaneous wound healing is a complicated multiatep process with numerous mediators that act in a network of activation and inhibition processes. Nonhealing chronic wounds decrease the quality of Life. Recombinant growth factors, currently used in clinic, fail to provide a sustained repair function at the wound due to their inadequate biological availability and transient half-time. Recent attention has focused on gene therapy, which might become a significant treatment modality for those wound healing pathologies refractory to other wound management approaches. This review discusses the potentials and limitations of current genetherapy for the treatment of wounds, current ongoing clinical trials, and possible future directions in this exciting field.